Home > For researchers > Preclinical tools and models
Preclinical tools and models in Hurler syndrome (MPS I-H)
Preclinical systems play a central role in understanding severe MPS I (Hurler syndrome) and in advancing therapeutic approaches such as systemic gene delivery, refined transplantation strategies and next-generation enzyme replacement.
This page outlines the core in vivo and in vitro platforms used in MPS I-H research and explains how they connect to biomarkers, efficacy endpoints and translational decision-making.
For researchers and research-focused clinicians. Scientific content intended to be used alongside primary literature, institutional guidance and regulatory advice.
Animal model • Cell culture • Assays mapped across organs
Why preclinical models matter in MPS I-H
Due to disease rarity and clinical variability, translational programmes in MPS I-H rely heavily on well-designed preclinical evidence.
Animal models used in Hurler syndrome research
Mouse models with targeted disruption of the Idua gene remain the most widely used systems, offering reproducible multi-organ pathology and progressive disease features.
Typical characteristics
- Severely reduced or absent IDUA enzymatic activity.
- Marked glycosaminoglycan accumulation in tissues and biofluids.
- Progressive visceral, skeletal and cardiac involvement.
- Central nervous system changes and reduced lifespan in severe variants.
Primary applications
- Dose selection and route comparison for systemic gene delivery.
- Assessment of enzyme replacement, transplant-based or adjunctive therapies.
- Longitudinal tracking of biomarkers, imaging and functional endpoints.
Cellular models and assay platforms
In vitro and ex vivo systems complement animal studies by supporting mechanistic insight and early screening.
Assays integrated with models
Enzyme activity
IDUA measurements in plasma, cells and tissue homogenates.
GAG profiling
Total and species-specific sulphated GAGs in biofluids and organs.
Histology & imaging
Storage burden, tissue architecture and advanced imaging where available.
Functional outcomes
Survival, motor performance and behavioural assessments.
Experimental design, controls and timing
- Careful selection of disease stage and intervention window.
- Appropriate wild-type and disease control groups.
- Clear dosing rationale and delivery strategy.
- Defined early and late assessment time points.
- Use of randomisation and blinded outcome assessment where feasible.
Tools for safety and biodistribution
- Vector copy number and integration analyses across tissues.
- Comprehensive organ biodistribution panels.
- Clinical pathology and targeted histopathology.
- Assessment of humoral and cellular immune responses.
Digital, computational and analytical tools
- Statistical pipelines for longitudinal and survival data.
- Image analysis for histology, bone and organ structure.
- Integrated datasets combining biochemical and functional outcomes.
- Exploratory translational and dose-scaling models.
Practical tips for building a preclinical toolbox
- Focus on a limited number of well-characterised core models.
- Define a consistent primary assay panel across studies.
- Add exploratory endpoints in a structured, hypothesis-driven way.
- Maintain detailed protocols suitable for regulatory submission.
- Align with emerging core outcome frameworks where possible.
Preclinical tools and models at a glance
- Animal models remain the backbone of translational MPS I-H research.
- Cellular systems add mechanistic and screening capability.
- Robust assays are essential for efficacy interpretation.
- Safety and biodistribution data underpin advanced therapies.